» Articles » PMID: 35677497

Risk Factors for Necrotic Cholecystitis During the COVID-19 Pandemic: the ChoCO-WSES Prospective Collaborative Study's Experience

Abstract

Objectives: During the COVID-19 pandemic, several studies have reported a decrease in in the admission surgical patients and emergency surgical procedures, and an increase in more severe septic surgical diseases, such as necrotic cholecystitis. It was probably due to to a critical delay in time-to- diagnosis and time-to-intervention resulting to limited access to the operating theatres as well as intensive care units. Early laparoscopic cholecystec- tomy is the standard of care for acute cholecystitis. Moreover early data from COVID-19 pandemic reported an increase in the incidence of necrotic cholecystitis among COVID-19 patients. The ChoCO-W prospective observational collaborative study was conceived to investigate the incidence and management of acute cholecystitis under the COVID-19 pandemic.

Material And Methods: The present research protocol was. conceived and designed as a prospective observational international collaborative study focusing on the management of patients with to the diagnosis of acute cholecystitis under the COVID-19 pandemic. The study obtained the approval of the local Ethics Committee (Nimes, France) and meet and conform to the standards outlined in the Declaration of Helsinki. Eligible patients will be prospectively enrolled in the recruitment period and data entered in an online case report form.

Results: The ChoCO-W study will be the largest prospective study carried out during the first period of the COVID-19 pandemic with the aim to inves- tigate the management of patients with acute cholecystitis, in the lack of studies focusing on COVID-19 positive patients.

Conclusion: The ChoCO-W study is conceived to be the largest prospective study to assess the management of patients presenting with acute chol- ecystitis during the COVID-19 pandemic and risk factors correlated with necrotic cholecystitis to improve the management of high-risk patients.

Citing Articles

COVID-19 infection is a significant risk factor for death in patients presenting with acute cholecystitis: a secondary analysis of the ChoCO-W cohort study.

De Simone B, Abu-Zidan F, Kasongo L, Moore E, Podda M, Sartelli M World J Emerg Surg. 2025; 20(1):16.

PMID: 40001181 PMC: 11853863. DOI: 10.1186/s13017-025-00591-w.


The ChoCO-W prospective observational global study: Does COVID-19 increase gangrenous cholecystitis?.

De Simone B, Abu-Zidan F, Chouillard E, Di Saverio S, Sartelli M, Podda M World J Emerg Surg. 2022; 17(1):61.

PMID: 36527038 PMC: 9755784. DOI: 10.1186/s13017-022-00466-4.

References
1.
Bourikian S, Anand R, Aboutanos M, Wolfe L, Ferrada P . Risk factors for acute gangrenous cholecystitis in emergency general surgery patients. Am J Surg. 2015; 210(4):730-3. DOI: 10.1016/j.amjsurg.2015.05.003. View

2.
Martinez Caballero J, Gonzalez Gonzalez L, Rodriguez Cuellar E, Ferrero Herrero E, Perez Algar C, Vaello Jodra V . Multicentre cohort study of acute cholecystitis management during the COVID-19 pandemic. Eur J Trauma Emerg Surg. 2021; 47(3):683-692. PMC: 7978438. DOI: 10.1007/s00068-021-01631-1. View

3.
Barabino M, Piccolo G, Trizzino A, Fedele V, Ferrari C, Nicastro V . COVID-19 outbreak and acute cholecystitis in a Hub Hospital in Milan: wider indications for percutaneous cholecystostomy. BMC Surg. 2021; 21(1):180. PMC: 8022294. DOI: 10.1186/s12893-021-01137-y. View

4.
Okamoto K, Suzuki K, Takada T, Strasberg S, Asbun H, Endo I . Tokyo Guidelines 2018: flowchart for the management of acute cholecystitis. J Hepatobiliary Pancreat Sci. 2017; 25(1):55-72. DOI: 10.1002/jhbp.516. View

5.
Asti E, Lovece A, Bonavina L . Gangrenous cholecystitis during hospitalization for SARS-CoV2 infection. Updates Surg. 2020; 72(3):917-919. PMC: 7249979. DOI: 10.1007/s13304-020-00814-6. View